Hims & Hers Health

HIMS

Market cap $6.05B

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, an.

As the market finds itself in the thick of Q2 earnings season, there is—per usual—a considerable amount of noise. Companies that have handily beaten consensus expectations have been punished, while others have seen their shares surge despite dramatically missing analyst forecasts.

Hims & Hers and Tempus AI are taking different paths in AI-driven healthcare, but which stock offers stronger upside now? Let's dive in.

Shares of Hims & Hers Health Inc (NYSE:HIMS) are trading higher Wednesday morning, fueled by a wave of investor confidence following an insider stock purchase by a key member of the company's leadership team. Here's what investors need to know.

Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy subscribers per quarter from the second through fourth quarters of 2026 to reach the midpoint of its full-year sales guidance.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.

Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a ​generic version of semaglutide, the active ingredient in ‌Novo Nordisk's blockbuster drug Ozempic, through its platform.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers' first international generic GLP-1 offering, demonstrating the company's ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making.